Clinical Trials Browser

NETWORK × Hodgkin Disease × Nivolumab × Clear all

NCT07209059 2025-10-06

FINISH-HL

Phase 2 Recruiting

Hodgkin Disease

NCT05660993 2022-12-21

Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma

Phase 2 Unknown

Hodgkin Disease